{"name":"Strides Pharma Science","slug":"strides-pharma","ticker":"STAR.NS","exchange":"NSE","domain":"stfridesglobal.com","description":"Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.","hq":"Bengaluru, Karnataka, India","founded":0,"employees":"3301","ceo":"","sector":"Regulated Market Generics — Soft Gelatin Capsules / Controlled Substances","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":1155.4,"stockChange":9,"stockChangePercent":0.79,"marketCap":"$1.1B","metrics":{"revenue":493520433.7096704,"revenueGrowth":3.6,"grossMargin":56.2,"rdSpend":0,"netIncome":53412740.994835205,"cash":23754765.460835204,"dividendYield":0.35,"peRatio":20.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":458646956.55075,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":458646956.55075},{"period":"2024-03-31","value":389546350.763625},{"period":"2023-03-31","value":376768264.89087504},{"period":"2022-03-31","value":315609551.63100004}],"grossProfit":235791161.04912502,"grossProfitHistory":[{"period":"2025-03-31","value":235791161.04912502},{"period":"2024-03-31","value":192836891.311625},{"period":"2023-03-31","value":194439765.44712502},{"period":"2022-03-31","value":145217806.67900002}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":44261174.02025,"operatingIncome":60531056.656125,"operatingIncomeHistory":[{"period":"2025-03-31","value":60531056.656125},{"period":"2024-03-31","value":33532423.511125002},{"period":"2023-03-31","value":14921830.815375},{"period":"2022-03-31","value":-25247356.341625}],"netIncome":375283820.47062504,"netIncomeHistory":[{"period":"2025-03-31","value":375283820.47062504},{"period":"2024-03-31","value":-7374390.6995},{"period":"2023-03-31","value":-21162262.213125},{"period":"2022-03-31","value":-48062308.364125006}],"eps":390.5,"epsHistory":[{"period":"2025-03-31","value":390.5},{"period":"2024-03-31","value":-7.76},{"period":"2023-03-31","value":-22.49},{"period":"2022-03-31","value":-51.28}],"cash":11755663.5515,"cashHistory":[{"period":"2025-03-31","value":11755663.5515},{"period":"2024-03-31","value":16816184.0825},{"period":"2023-03-31","value":31696240.747875},{"period":"2022-03-31","value":17830251.57375}],"totalAssets":631700863.646875,"totalLiabilities":361582525.882875,"totalDebt":196300177.217375,"equity":266501427.42162502,"operatingCashflow":71472855.33025001,"operatingCashflowHistory":[{"period":"2025-03-31","value":71472855.33025001},{"period":"2024-03-31","value":73215986.17437501},{"period":"2023-03-31","value":4638079.4391250005},{"period":"2022-03-31","value":-26925006.205625}],"capex":-25325369.56675,"capexHistory":[{"period":"2025-03-31","value":-25325369.56675},{"period":"2024-03-31","value":-12339143.991625002},{"period":"2023-03-31","value":-9914885.63175},{"period":"2022-03-31","value":-14974257.373625001}],"freeCashflow":46147485.763500005,"dividendsPaid":-2400969.27125,"buybacks":null,"employees":3301,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":30166575.810250003,"ebitda":35453407.798875004,"period":"2025-12-31","revenue":124763303.00225002,"epsBasic":21.93,"netIncome":21107120.335125003,"rdExpense":null,"epsDiluted":21.92,"grossProfit":76415886.064375,"operatingIncome":19354172.565750003},{"sga":null,"ebit":17702109.368625,"ebitda":22807537.110875003,"period":"2025-06-30","revenue":116940049.061,"epsBasic":10.81,"netIncome":10402598.833,"rdExpense":null,"epsDiluted":10.81,"grossProfit":70541187.349875,"operatingIncome":17669212.225500003},{"sga":null,"ebit":12039205.594625002,"ebitda":17141918.017125003,"period":"2025-03-31","revenue":106183623.17750001,"epsBasic":null,"netIncome":8583961.21275,"rdExpense":null,"epsDiluted":null,"grossProfit":37996618.050875,"operatingIncome":14418243.437125001},{"sga":null,"ebit":17339092.005125,"ebitda":22396270.604125,"period":"2024-12-31","revenue":120483645.770125,"epsBasic":9.56,"netIncome":9184673.48975,"rdExpense":null,"epsDiluted":9.55,"grossProfit":70341715.783625,"operatingIncome":16906833.988},{"sga":null,"ebit":16713001.932000002,"ebitda":21773209.156875003,"period":"2024-09-30","revenue":121869189.89025001,"epsBasic":7.81,"netIncome":7502950.646125001,"rdExpense":null,"epsDiluted":7.8,"grossProfit":64323105.122375004,"operatingIncome":14218980.741625002}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1155.4,"previousClose":1146.4,"fiftyTwoWeekHigh":1231,"fiftyTwoWeekLow":654.4,"fiftyTwoWeekRange":"654.4 - 1231.0","fiftyDayAverage":986.79,"twoHundredDayAverage":904.93,"beta":0.31,"enterpriseValue":1285753679.0337536,"forwardPE":15.9,"priceToBook":3.86,"priceToSales":2.25,"enterpriseToRevenue":2.6,"enterpriseToEbitda":14.46,"pegRatio":0,"ebitda":88903278.15952,"ebitdaMargin":18,"freeCashflow":0,"operatingCashflow":0,"totalDebt":192563469.30698243,"debtToEquity":65.8,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":2,"targetMeanPrice":1264,"targetHighPrice":1409,"targetLowPrice":1119,"dividendRate":4,"payoutRatio":0.07,"fiveYearAvgDividendYield":1.23,"exDividendDate":1753142400,"insiderHeldPercent":30.8,"institutionHeldPercent":27,"sharesOutstanding":92172714,"floatShares":56689492,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":55.49,"epsForward":72.55,"revenuePerShare":512.72,"bookValue":299.06,"officers":[{"age":64,"name":"Mr. Arun Kumar Pillai B.Com.","title":"Founder & Non-Executive Chairperson"},{"age":53,"name":"Mr. Badree  Komandur","title":"MD & Group CEO"},{"age":40,"name":"Mr. Vikesh  Kumar","title":"Group CFO"},{"age":null,"name":"Ms. Manjula  Ramamurthy","title":"Compliance Officer & Company Secretary"},{"age":null,"name":"Mr. Aditya Arun Kumar","title":"Executive Director of Business Development & Director"},{"age":null,"name":"Mr. P. V. S. Ramaraju","title":"Chief Operating Officer"},{"age":null,"name":"Ms. Sormistha  Ghosh","title":"Group General Counsel, Chief Risk Officer & Chief Sustainability Officer"},{"age":null,"name":"Ms. Nandini  Matiyani","title":"Executive Vice President of Human Resources"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.strides.com","phone":"91 80 6784 0000"}}